JnJ Executive Committee Changes

With Sandi Peterson's departure, JnJ has decided to reshuffle/promote its senior leaders. Any thoughts? Any misses? Any surprises?

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

JnJ should be separated. It's too big and frankly the executive committee is just after big growth, so its focus is primarily in pharmaceutical to the detriment of the other divisions.

post

That's pretty sad, contact lenses will be commoditized soon enough, its 2 pieces of plastic (seriously) and JJVC was on the losing end not too long ago and its basically a 3-way market share for the longest time.

BWI, let's just hope this is not the next mesh/hip implant/risperdal/talc. Considering that the longest study to look at ablation concluded that there is no difference between drug and ablation and the fact that this is not a cure, why pay for someone to mutilate your heart (so many are already spinning the results, its just sad; what happened to academic credibility?). Sales people are just pushing their doctors to do more and EPs are doing it because it pays well and they get a guaranteed repeat customer since most ablation need a repeat or 2. The first thing AHA/ACC should do is tighten the criteria for who gets ablation.

I feel for Synthes the most. They should have stayed the course or merged with either Zimmer, Stryker or Medtronic. I think Synthes would have fared better than what it is now :(.

Synthes has already been divested to Jabil, for all intents & purposes.

post

BWI & Contact lenses are growing. The rest of med devices is either not growing and/or losing market share to competitors.

As for the next great divestiture, Acclarent, Mentor, AMO, & DePuy are the upcoming possibilities.

That's pretty sad, contact lenses will be commoditized soon enough, its 2 pieces of plastic (seriously) and JJVC was on the losing end not too long ago and its basically a 3-way market share for the longest time.

BWI, let's just hope this is not the next mesh/hip implant/risperdal/talc. Considering that the longest study to look at ablation concluded that there is no difference between drug and ablation and the fact that this is not a cure, why pay for someone to mutilate your heart (so many are already spinning the results, its just sad; what happened to academic credibility?). Sales people are just pushing their doctors to do more and EPs are doing it because it pays well and they get a guaranteed repeat customer since most ablation need a repeat or 2. The first thing AHA/ACC should do is tighten the criteria for who gets ablation.

I feel for Synthes the most. They should have stayed the course or merged with either Zimmer, Stryker or Medtronic. I think Synthes would have fared better than what it is now :(.

post

How is Ashley handling the entire med device, yay or nay? What's next on the chopping block now that ASP is done?

BWI & Contact lenses are growing. The rest of med devices is either not growing and/or losing market share to competitors.

As for the next great divestiture, Acclarent, Mentor, AMO, & DePuy are the upcoming possibilities.

post

How is Ashley handling the entire med device, yay or nay? What's next on the chopping block now that ASP is done?

post

The report looks terrible for JNJ yet they do the only thing they know how: Deny, deny, deny.

Risperdal. Hip implants. Baby Powder. But Teflon Alex will never see the stand. What about the CrAYdOH?

post

JnJ stocks down 10% from the last article I read this weekend. How much more will it slide knowing that corrupt JnJ is now getting known around the world. Talc and Asbestos in Consumer; Actelion (JnJ's most recent acquisition) recently settled allegations of kickback in the US (don't forget Risperdal, I am sure those boys who grew breast does not!); Medical devices and Sales people in the OR (I really don't buy doctors/hospitals excuses of needing sales people in the OR because they know the products, if you're my freaking doctor, I expect you to know the products your putting/using in me and not the sales person, THIS IS YOUR JOB!!! YOU NEED TO STOP BEING LAZY. You need to do less stroking of your ego and more about knowing the products you're using in people). This tells me that people in JnJ are not only greedy, it tells me that this so called CREDO is a bunch of bullshit; well there's one section that's correct, the section about stockholders! :(...

The report looks terrible for JNJ yet they do the only thing they know how: Deny, deny, deny.

post

JnJ stocks down 10% from the last article I read this weekend. How much more will it slide knowing that corrupt JnJ is now getting known around the world. Talc and Asbestos in Consumer; Actelion (JnJ's most recent acquisition) recently settled allegations of kickback in the US (don't forget Risperdal, I am sure those boys who grew breast does not!); Medical devices and Sales people in the OR (I really don't buy doctors/hospitals excuses of needing sales people in the OR because they know the products, if you're my freaking doctor, I expect you to know the products your putting/using in me and not the sales person, THIS IS YOUR JOB!!! YOU NEED TO STOP BEING LAZY. You need to do less stroking of your ego and more about knowing the products you're using in people). This tells me that people in JnJ are not only greedy, it tells me that this so called CREDO is a bunch of bullshit; well there's one section that's correct, the section about stockholders! :(...

post

There is a ton of product overlap with Boston Sci. I dont think they will invest in the device space.

If BSci wants to die a horrible death, then they should try to get bought out by JnJ..... lol!!

post

It won't happen but Boston Scientific would be a perfect fit.

There is a ton of product overlap with Boston Sci. I dont think they will invest in the device space.

post

I agree with both of you which makes it even more frustrating. Ha. What device company would JNJ even buy if they went that direction? I think whatever move they make it has to be substantial.

It won't happen but Boston Scientific would be a perfect fit.

post

Seems JnJ has been buying companies in Pharma and Consumer but no Devices in the last few months. Wonder if this is strategic :P lol

I agree with both of you which makes it even more frustrating. Ha. What device company would JNJ even buy if they went that direction? I think whatever move they make it has to be substantial.

post

No doubt the MDD sector has been a clown show. Could not agree more on the acquisition failures. Synthes has been a total disaster! The global device sector has a lot of growth opportunity, especially in robotics and structural heart valves; but it seems like J&J MDD would rather continue to invest in a declining Spine market and focus on other ventures instead of meaningful innovation in most of its existing platforms.

Seems JnJ has been buying companies in Pharma and Consumer but no Devices in the last few months. Wonder if this is strategic :P lol

post

Bingo, was this even a secret? No real growth, all acquisitions virtually a failure (Synthes, Mentor, Acclarent, dare I say AMO?!). JnJ exited interventional cardiology but now want to play in stroke prevention and management. Look at CIA for Synthes and ASP. Look at the dwindling market share. Look at recalls. Look at robotics (or rather squint to see if you can make up anything, lol). Look at all the pending cases and class action, can anyone say mesh, hip implant. And really look at employee morale, this is by far the strongest indicator that things aren't where it's suppose to be.

No doubt the MDD sector has been a clown show. Could not agree more on the acquisition failures. Synthes has been a total disaster! The global device sector has a lot of growth opportunity, especially in robotics and structural heart valves; but it seems like J&J MDD would rather continue to invest in a declining Spine market and focus on other ventures instead of meaningful innovation in most of its existing platforms.

post

I am assuming they mean that JnJs device portfolio and the people running MDD are awful?

Bingo, was this even a secret? No real growth, all acquisitions virtually a failure (Synthes, Mentor, Acclarent, dare I say AMO?!). JnJ exited interventional cardiology but now want to play in stroke prevention and management. Look at CIA for Synthes and ASP. Look at the dwindling market share. Look at recalls. Look at robotics (or rather squint to see if you can make up anything, lol). Look at all the pending cases and class action, can anyone say mesh, hip implant. And really look at employee morale, this is by far the strongest indicator that things aren't where it's suppose to be.

post

Loading...


Load More

Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.